Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022. The company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.55 EUR | -0.73% | -5.57% | -53.60% |
May. 22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
Apr. 16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-53.60% | 22.89M | |
-0.35% | 90.85B | |
-0.92% | 39.02B | |
-9.57% | 33.46B | |
-17.98% | 14.51B | |
-6.74% | 13.22B | |
-9.76% | 11.65B | |
-47.31% | 10.57B | |
+6.52% | 9.23B | |
+137.06% | 7.71B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022